Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.
Andrew J Solomon, Georgina Arrambide, Wallace J Brownlee...
https://pubmed.ncbi.nlm.nih.gov/37479377/Actively Recruiting
Led by Tongji Hospital · Updated on 2026-07-29
50000
Participants Needed
1
Research Sites
N/A
Total Duration
Neurological autoimmune diseases involve an abnormal immune response that attacks the nervous system, including the brain, spinal cord, and peripheral nerves. These diseases are complex, with varied symptoms and difficulty in diagnosis and management due to limited treatment options. This research focuses on eight neurological autoimmune diseases such as Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, idiopathic inflammatory myopathy, multiple sclerosis, autoimmune encephalitis, and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. The goal is to find biomarkers that can help with early diagnosis, monitoring, and personalized treatment to improve patient outcomes and quality of life. The study will investigate and validate new biomarkers found in blood, feces, bone marrow, lymph nodes, and other sources for these neurological autoimmune conditions. Participants will include individuals clinically diagnosed with these diseases and healthy volunteers matched by age and sex. The study involves diagnostic testing to identify sensitive and specific biomarkers that can support disease understanding and management. Participants will be observed over a long-term period, with researchers collecting samples and data to measure all-cause mortality over 10 years as the primary outcome. Secondary outcomes include the occurrence of any autoimmune disease within 10 years. The study includes clinical assessments and advanced molecular analyses such as proteomics, metabolomics, miRNA sequencing, and single-cell transcriptome sequencing to explore disease mechanisms and prognosis. This observational study will provide important information to guide future personalized therapies and improve care for patients with neurological autoimmune diseases.
CONDITIONS
Biomarkers in Autoimmune Disease of Nervous System
L
Luo-qi Zhou, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tongji Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Andrew J Solomon, Georgina Arrambide, Wallace J Brownlee...
https://pubmed.ncbi.nlm.nih.gov/37479377/Egon Stenager
https://pubmed.ncbi.nlm.nih.gov/30679041/Rhoanne C McPherson, Stephen M Anderton
https://pubmed.ncbi.nlm.nih.gov/23568718/Tongji Hospital
Lead Sponsor